Interestingly, SGLT-2 have been demonstrated to reduce CV events mainly through their effect on obesity and BP rather than their impact on blood glucose levels [95,96]. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.